A Multicentre Phase II Study of Adavosertib Plus Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Trial ID #	NCT02272790
Phase	II
Drug Class	Cell Cycle Inhibitors: Wee1
Drug Name	Adavosertib
Alternate Drug Names	WEE1 inhibitor AZD1775, MK1775, AZD1775
Drugs in Trial	Adavosertib, Carboplatin
Eligible Participant	Primary platinum resistant ovarian cancer
Patients Enrolled	35, median 2 prior therapies
Therapy Setting	Recurrence
Study Design	Open-Label, Non-randomized
Endpoints	ORR, DCR, DoR, PFS, evaluated per RECIST
Efficacy	Ada W1+CarboPt: 225 mg Ada BID week 1 (day 1-3)+CarboPt AUC5 Ada W1-3+CarboPt: 225 mg Ada BID weeks 1-3 (day 1-3, 8-10, 15-17)+CarboPt AUC5 AdaW1+CarboPt: ORR: 30.4% (1CR, 6PR, n=23); DCR: 82.6% (1CR, 6PR, 12SD, n=23); PFS: 4.2 months Ada W1-3+CarboPt: ORR: 66.7% (1CR, 7PR, n=12); DCR: 100% (1CR, 7PR, 4SD, n=12); DoR: 10.4 months; PFS: 12.0 months - 3 patients w/ CCNE1 AMP had PR
Clinically Significant Adverse Events	Serious AE: Grade 3-4AE: W1+C: anemia (56.5%), thrombocytopenia (52.2%), neutropenia (21.7%), diarrhea (17.4%), vomiting (13.0%) Grade 3-4 AE: W1-3+C: thrombocytopenia (83.3%), neutropenia (75.0%), anemia (58.3%)
Reference	Moore KN et al. Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: an Open-Label, Four-Arm, Phase II Study. Clin Cancer Res (2022) 28(1):36-44 https://pubmed.ncbi.nlm.nih.gov/34645648/